Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proprotein convertase subtilisin/kexin type 9 inhibition.
Marais DA, Blom DJ, Petrides F, Gouëffic Y, Lambert G. Marais DA, et al. Among authors: lambert g. Curr Opin Lipidol. 2012 Dec;23(6):511-7. doi: 10.1097/MOL.0b013e3283587563. Curr Opin Lipidol. 2012. PMID: 22907332 Review.
The promises of PCSK9 inhibition.
Petrides F, Shearston K, Chatelais M, Guilbaud F, Meilhac O, Lambert G. Petrides F, et al. Among authors: lambert g. Curr Opin Lipidol. 2013 Aug;24(4):307-12. doi: 10.1097/MOL.0b013e328361f62d. Curr Opin Lipidol. 2013. PMID: 23817198 Review.
Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD. Lambert G, et al. J Am Coll Cardiol. 2014 Jun 10;63(22):2365-73. doi: 10.1016/j.jacc.2014.02.538. Epub 2014 Mar 12. J Am Coll Cardiol. 2014. PMID: 24632287 Free article.
Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A, Sjouke B, Passard M, Prampart-Fauvet S, Guédon A, Croyal M, Dallinga-Thie G, Peter J, Blom D, Ciccarese M, Cefalù AB, Pisciotta L, Santos RD, Averna M, Raal F, Pintus P, Cossu M, Hovingh K, Lambert G. Thedrez A, et al. Among authors: lambert g. Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1647-50. doi: 10.1161/ATVBAHA.116.307493. Epub 2016 Apr 14. Arterioscler Thromb Vasc Biol. 2016. PMID: 27079874
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Arsenault BJ, et al. Among authors: lambert g. J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12. J Clin Lipidol. 2018. PMID: 29103916 Clinical Trial.
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G. Thedrez A, et al. Among authors: lambert g. Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):592-598. doi: 10.1161/ATVBAHA.117.310217. Epub 2017 Dec 28. Arterioscler Thromb Vasc Biol. 2018. PMID: 29284604 Free PMC article. Clinical Trial.
Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
Huijgen R, Blom DJ, Hartgers ML, Chemello K, Benito-Vicente A, Uribe KB, Behardien Z, Blackhurst DM, Brice BC, Defesche JC, de Jong AG, Jooste RJ, Solomon GAE, Wolmarans KH, Hovingh GK, Martin C, Lambert G, Marais AD. Huijgen R, et al. Among authors: lambert g. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):934-943. doi: 10.1161/ATVBAHA.120.314482. Epub 2020 Nov 5. Arterioscler Thromb Vasc Biol. 2021. PMID: 33147992 Free article.
Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, Dikkeschei BD, Navis G, Dullaart RP. Kwakernaak AJ, et al. Among authors: lambert g. Atherosclerosis. 2013 Feb;226(2):459-65. doi: 10.1016/j.atherosclerosis.2012.11.009. Epub 2012 Nov 29. Atherosclerosis. 2013. PMID: 23261172 Clinical Trial.
PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab.
Villard EF, Thedrez A, Blankenstein J, Croyal M, Tran TT, Poirier B, Le Bail JC, Illiano S, Nobécourt E, Krempf M, Blom DJ, Marais AD, Janiak P, Muslin AJ, Guillot E, Lambert G. Villard EF, et al. Among authors: lambert g. JACC Basic Transl Sci. 2016 Oct;1(6):419-427. doi: 10.1016/j.jacbts.2016.06.006. JACC Basic Transl Sci. 2016. PMID: 29308438 Free PMC article.
1,294 results